The design of dual thromboxane synthase inhibitor/thromboxane receptor
antagonists (e.g, 15) based on the structure of the thromboxane synth
ase inhibitor dazmegrel is described. More potent receptor antagonists
(e.g, 16c) result from replacement of the pyridinyl subsituent with 4
-fluorophenyl. Modelling suggests the existence of more than one site
capable of interacting with the aryl sulfonamide of TxA(2) receptor an
tagonists. Copyright (C) 1996 Elsevier Science Ltd